Israel Non-Small Cell Lung Cancer Diagnostics Market to 2032
Overview
The Israel Non-Small Cell Lung Cancer Diagnostics Market is expected to reach a 37.37 USD Million by 2032 and is projected to grow at a CAGR of 18.25% from 2025 to 2032.
Revenue, 2024 (USD Million)
15.73
Forecast, 2032 (USD Million)
37.37
CAGR, 2024 - 2032
18.25%
Report Coverage
Israel
Israel Non-Small Cell Lung Cancer Diagnostics Market 2018-2032 USD Million
Israel Non-Small Cell Lung Cancer Diagnostics Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 15.73 USD Million
- Projected Market Size (2032): 37.37 USD Million
- CAGR (2025-2032): 18.25%
Key Findings of Israel Non-Small Cell Lung Cancer Diagnostics Market
- The Israel Non-Small Cell Lung Cancer Diagnostics Market was valued at 15.73 USD Million in 2024.
- The Israel Non-Small Cell Lung Cancer Diagnostics Market is likely to grow at a CAGR of 18.25% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Lung Adenocarcinoma (LUAD) in Lung Cancer Type Segment accounted for the largest share of the market with a revenue of 9.15 USD Million
- The fastest growing segment Imaging Test in Test Segment grew Fastest with a CAGR of 21.61% during the forecast period from 2024 to 2032.
Israel Non-Small Cell Lung Cancer Diagnostics Market Scope
Israel Non-Small Cell Lung Cancer Diagnostics Market Segmentation & Scope
Lung Cancer Type
- Others
- Large Cell Carcinoma
- Lung Squamous CellCarcinoma (LUSC)
- Lung Adenocarcinoma (LUAD)
Product
- Services and Softwares
- Reagents and Kits
- Instruments
Test
- Thorecentesis
- Sputum Cytology
- Others
- Biopsy
- Immunohistochemistry
- Imaging Test
- Molecular Test
End User
- Institutes and Research Centers
- Academics
- Hospital
- Clinical Laboratories
Israel Non-Small Cell Lung Cancer Diagnostics Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2020 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 15.73 USD Million |
| Market Value in 2032 | 37.37 USD Million |
| CAGR (2025-2032) | 18.25% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Lung Cancer Type,Product,Test,End User |
Regional Insights:
-
Leading Market (2024-2032): Israel, leading in terms of revenue 15.73 USD Million in 2024
- Key Country: Israel, leading in terms of revenue with value of 15.73 USD Million in 2024.
Segments and Scope
-
Israel Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Lung Cancer Type
- Lung Adenocarcinoma (LUAD) is the largest segment in Israel Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 9.15 USD Million in the year 2024.
- Lung Adenocarcinoma (LUAD) is the Fastest growing segment in Israel Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 18.56 % in forecast period 2025-2032.
-
Israel Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Product
- Instruments is the largest segment in Israel Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 7.50 USD Million in the year 2024.
- Reagents and Kits is the Fastest growing segment in Israel Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 17.75 % in forecast period 2025-2032.
-
Israel Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Test
- Imaging Test is the largest segment in Israel Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 6.55 USD Million in the year 2024.
- Imaging Test is the Fastest growing segment in Israel Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 21.61 % in forecast period 2025-2032.
-
Israel Non-Small Cell Lung Cancer Diagnostics Market to 2032, By End User
- Clinical Laboratories is the largest segment in Israel Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 7.81 USD Million in the year 2024.
- Clinical Laboratories is the Fastest growing segment in Israel Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 18.93 % in forecast period 2025-2032.
Israel Non-Small Cell Lung Cancer Diagnostics Market Company Share Analysis
| Company Name |
|
||
| QIAGEN | |||
| Quest Diagnostics Incorporated | |||
| Abbott | |||
| General Electric | |||
| F. Hoffmann-La Roche Ltd. | |||
Israel Non-Small Cell Lung Cancer Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Million
Israel Non-Small Cell Lung Cancer Diagnostics Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Israel Non-Small Cell Lung Cancer Diagnostics Market is segmented based on Segmentation Lung Cancer Type,Product,Test,End User.
Israel Non-Small Cell Lung Cancer Diagnostics Market was valued at USD 15.73(Revenue in USD Million) in 2020.
Israel Non-Small Cell Lung Cancer Diagnostics Market is projected to grow at a CAGR of 18.25% during the forecast period of 2024 to 2032.
The Lung Adenocarcinoma (LUAD) segment is expected to dominate the Israel Non-Small Cell Lung Cancer Diagnostics Market, holding a largest market share of 9.15 USD Million in 2024
Israel Non-Small Cell Lung Cancer Diagnostics Market Scope
Israel Non-Small Cell Lung Cancer Diagnostics Market Segmentation & Scope
Lung Cancer Type
- Others
- Large Cell Carcinoma
- Lung Squamous CellCarcinoma (LUSC)
- Lung Adenocarcinoma (LUAD)
Product
- Services and Softwares
- Reagents and Kits
- Instruments
Test
- Thorecentesis
- Sputum Cytology
- Others
- Biopsy
- Immunohistochemistry
- Imaging Test
- Molecular Test
End User
- Institutes and Research Centers
- Academics
- Hospital
- Clinical Laboratories
Frequently Asked Questions
The Israel Non-Small Cell Lung Cancer Diagnostics Market is segmented based on Segmentation Lung Cancer Type,Product,Test,End User.
Israel Non-Small Cell Lung Cancer Diagnostics Market was valued at USD 15.73(Revenue in USD Million) in 2020.
Israel Non-Small Cell Lung Cancer Diagnostics Market is projected to grow at a CAGR of 18.25% during the forecast period of 2024 to 2032.
The estimated market value of the Israel Non-Small Cell Lung Cancer Diagnostics Market for final year is USD 37.37 (USD Million).
Israel Non-Small Cell Lung Cancer Diagnostics Market Company Profiling
Frequently Asked Questions
The Israel Non-Small Cell Lung Cancer Diagnostics Market is segmented based on Segmentation Lung Cancer Type,Product,Test,End User.
Israel Non-Small Cell Lung Cancer Diagnostics Market was valued at USD 15.73(Revenue in USD Million) in 2020.
Israel Non-Small Cell Lung Cancer Diagnostics Market is projected to grow at a CAGR of 18.25% during the forecast period of 2024 to 2032.
The estimated market value of the Israel Non-Small Cell Lung Cancer Diagnostics Market for final year is USD 37.37 (USD Million).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.